Commentary

These images of diabetic retinopathy tell the story better


 

I read, with great interest, Dr. Farford’s thorough review article “Diabetic retinopathy: the FP’s role in preserving vision” (J Fam Pract. 2020;69:120-126). I am a family physician with ophthalmology training. For more than 20 years, I have regularly performed dilated eye exams and reviewed nonmydriatic fundus photos for uninsured patients with diabetic retinopathy (DR) at the community health clinic where I work. The burden of visual loss from poorly controlled diabetes is staggering.

I do, however, want to point out some inaccuracies in the labeling of 2 of the photos included in Table 1.

  • The photo labeled “Severe NPDR [nonproliferative DR]”—Figure 1A—actually shows an eye that has been treated with panretinal photocoagulation (multiple laser scars present in all quadrants) with nice regression of DR. Along the superior temporal arcade there is fibrosis, which likely represents regression of vitreal neovascularization or resolution of vitreal hemorrhage. There is little apparent active DR in this photo. The caption indicated the presence of intraretinal microvascular abnormalities; however, while these abnormalities may be present, they are not evident due to the photo resolution.
  • The photo labeled “Proliferative diabetic retinopathy”—Figure 2a—does not show evidence of neovascularization of the disc or the retina. This photo would be more accurately labeled “severe DR with likely clinically significant macular edema.”

The 2 photos shown here, from my photo collection, are perhaps more instructive:

  • FIGURE 1B is an example of severe NPDR and maculopathy (this eye has undergone previous panretinal photocoagulation, a treatment option for severe NPDR and proliferative DR [defined as new vessel growth or neovascularization]).
  • FIGURE 2b is an example of proliferative DR with vitreal hemorrhage that can lead to irreversible visual loss via traction retinal detachment.
Nonmydriatic fundus photos

I appreciate your efforts in publishing Dr. Farford’s article. DR is a broad, complicated topic, and this informative article will help many FPs.

Kenneth Libre, MD
Central City Community Health Center
Salt Lake City, UT

Recommended Reading

Geriatric patients: My three rules for them
MDedge Family Medicine
AHA scientific statement highlights cardiorenal benefit of new diabetes drugs
MDedge Family Medicine
British protocol allows insulin-treated pilots to fly safely
MDedge Family Medicine
Dapagliflozin’s CKD performance sends heart failure messages
MDedge Family Medicine
Time to screen for liver disease in type 2 diabetes?
MDedge Family Medicine
PPIs associated with diabetes risk, but questions remain
MDedge Family Medicine
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan
MDedge Family Medicine
Choosing Wisely: 10 practices to stop—or adopt—to reduce overuse in health care
MDedge Family Medicine
Chronic, nonhealing leg ulcer
MDedge Family Medicine
T2D treatments create tension between glycemic and cardiovascular goals
MDedge Family Medicine